Seragon Publishes Data for Longevity Drug SRN-901 Showing Significant Lifespan and Healthspan Extension
IRVINE, Calif., April 15, 2026 /PRNewswire/ -- Seragon Biosciences Inc. today announced the publication of comprehensive preclinical study results in the peer-reviewed journal Drug Design, Development and Therapy, demonstrating that its investigational combinatorial longevity drug, SRN-901, significantly extended median remaining lifespan and attenuated frailty progression in adult mice.
The published study highlights the potential of SRN-901 as a multi-target combinatorial approach to promote healthy aging and extend lifespan by targeting multiple aging pathways.
"Developing interventions to delay aging and improve lifespan and healthspan is a critical goal in aging research, yet individual geroprotective compounds fail to address the complexity, interconnectedness, and dynamic nature of biological systems," said David Scieszka, Ph.D., MBA, Chief Scientific Officer, Seragon Biosciences. "The robust multi-omics findings and physiological evidence from this study reinforce the rationale for combinatorial therapeutic approaches in aging research. By simultaneously targeting multiple aging pathways, SRN-901 provides a coherent mechanistic framework for promoting cellular resilience, reducing frailty, and suppressing key drivers of aging-related diseases."
Key Efficacy and Multi-Omics Findings:
About the Study The preclinical study investigated the effects of SRN-901 on lifespan extension, frailty reduction, disease-related gene expression pathways, metabolic aging, and the proteome in 18-month-old C57BL/6 mice fed a Western diet. Mice were treated until death with SRN-901 (500 mg/kg/day), placebo, or benchmark anti-aging compounds (rapamycin, NMN, or NR) via oral gavage. Frailty assessments were conducted before and after dosing, and blood samples were collected for comprehensive transcriptomic, metabolomic, and proteomic analyses to evaluate molecular correlates of longevity.
About SRN-901 SRN-901 is a novel oral combinatorial drug consisting of advanced longevity-associated compounds and Seragon's SRN-820. The combination acts as a multi-target intervention designed to simultaneously modulate interconnected nutrient-sensing, mitochondrial surveillance, and stress-response networks.
About Seragon Biosciences
Seragon Biosciences Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Biosciences is committed to applying cutting-edge scientific and technological advancements to the fields of aging, metabolism, oncology, and neurodegenerative diseases. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com.
Media Contact:
[email protected]
SOURCE Seragon Biosciences